Recombinant IL-11 approved as platelet booster.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D017370:Interleukin-11; D011994:Recombinant Proteins; C105308:oprelvekin